Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 10/2021

01.10.2021 | Neurology of Systemic Diseases (J. Biller, Section Editor)

Cerebrovascular Complications of Anemia

verfasst von: Ana Catarina Fonseca, Daniela P. Silva, Joana Infante, José M. Ferro

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 10/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of the Review

Anemia has been called the fifth cardiovascular risk factor. It is one of the most prevalent pathologies worldwide. In this article, we aimed to perform a narrative review of the main cerebrovascular complications of anemia and its influence on stroke prognosis.

Recent Findings

Both hypoproliferative anemia (thalassemia, iron deficiency anemia, etc.) and hyperproliferative anemia (sickle cell disease, paroxysmal nocturnal hemoglobinuria, hereditary spherocytosis, etc.) are associated to cerebrovascular disease ranging from transient ischemic attack to ischemic stroke and hemorrhagic stroke with both intraparenchymal hemorrhage and subarachnoid hemorrhage or cerebral venous thrombosis. Anemia is associated to a worse prognosis in patients with cerebrovascular disease

Summary

In some cases, like sickle cell disease, pathophysiological mechanisms and therapeutic guidelines are well established, while in others, due to their rarity, there are still lack of robust data. More studies are needed to clarify how the prognosis of stroke patients with anemia could be improved.
Literatur
1.
Kaiafa G, Kanellos I, Savopoulos C, Kakaletsis N, Giannakoulas G, Hatzitolios A. Is anemia a new cardiovascular risk factor? Int J Cardiol. 2015;186:117–24.PubMedCrossRef
2.
Lopez A, Cacoub P, Macdougall I, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016;387(10021):907–16.PubMedCrossRef
3.
World Health Organization. Nutritional anaemias: report of a WHO scientific group. Geneva: World Health Organization; 1968.
4.
Kasper DL, Fauci AS, Hauser S, et al editors. Harrison’s principles of internal medicine. 20th ed. New York: The McGraw-Hill Companies; 2018.
5.
6.
•• Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155–67. This is a comprehensive review about pathophysiology, clinical manifestations, and management of thalassemias.
7.
Weatherall DJ. The evolving spectrum of the epidemiology of thalassemia. Hematol Oncol Clin N Am. 2018;32(2):165–75.CrossRef
8.
Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet 2012;379(9813):373–83.
9.
Cappellini MD, Poggiali E, Taher AT, Musallam KM. Hypercoagulability in β-thalassemia: a status quo. Expert Rev Hematol. 2012;5(5):505–11.PubMedCrossRef
10.
11.
• Sleiman J, Tarhini A, Bou-Fakhredin R, Saliba AN, Cappellini MD, Taher AT. Non-transfusion-dependent thalassemia: an update on complications and management. Int J Mol Sci. 2018;19(1):182. This study reviews complications and management of non-transfusion-dependent thalassemias, highlighting the pathophysiology related to the hypercoagulability state and its risk factors.
12.
Marcon A, Motta I, Taher AT, Cappellini MD. Clinical complications and their management. Hematol Oncol Clin N Am. 2018;32(2):223–36.CrossRef
13.
Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886–92.PubMedCrossRef
14.
Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost. 2010;8(10):2152–8.PubMedCrossRef
15.
Logothetis J, Constantoulakis M, Economidou J, Stefanis C, Hakas P, Augoustaki O, et al. Thalassemia major (homozygous beta-thalassemia). A survey of 138 cases with emphasis on neurologic and muscular aspects. Neurology. 1972;22(3):294–304.PubMedCrossRef
16.
Haghpanah S, Karimi M. Cerebral thrombosis in patients with beta-thalassemia: a systematic review. Blood Coagul Fibrinolysis. 2012;23(3):212–7.PubMedCrossRef
17.
Taher A, Isma’eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96(4):488–91.PubMedCrossRef
18.
Karimi M, Khanlari M, Rachmilewitz EA. Cerebrovascular accident in beta-thalassemia major (beta-TM) and beta-thalassemia intermedia (beta-TI). Am J Hematol. 2008;83(1):77–9.PubMedCrossRef
19.
Vassilopoulou S, Anagnostou E, Paraskevas G, Spengos K. Etiology and treatment of ischaemic stroke in patients with β-thalassemia major. Eur J Neurol. 2011;18(12):1426–8. PubMedCrossRef
20.
Ramamoorthy J, Trehan A, Ahluwalia J, Singh P, Manoj R, Bansal D. Neuroimaging abnormalities in patients with nontransfusion-dependent thalassemia. J Pediatr Hematol Oncol. 2019;41(5):e290–5.PubMedCrossRef
21.
Teli A, Economou M, Rudolf J, Tzovaras F, Gourtsa V, Kondou A, et al. Subclinical central nervous system involvement and thrombophilic status in young thalassemia intermedia patients of Greek origin. Blood Coagul Fibrinolysis. 2012;23(3):195–202.PubMedCrossRef
22.
Karimi M, Haghpanah S, Bagheri MH, Bordbar MR, Pishdad P, Rachmilewitz EA. Frequency and distribution of asymptomatic brain lesions in patients with β-thalassemia intermedia. Ann Hematol. 2012;91:1833–8.PubMedCrossRef
23.
Karimi M, Toosi F, Haghpanah S, Pishdad P, Avazpour A, Rachmilewitz EA. The frequency of silent cerebral ischemia in patients with transfusion-dependent β-thalassemia major. Ann Hematol. 2016;95(1):135–9.PubMedCrossRef
24.
Karimi M, Bagheri H, Rastgu F, Rachmilewitz EA. Magnetic resonance imaging to determine the incidence of brain ischaemia in patients with beta-thalassaemia intermedia. Thromb Haemost. 2010;103(5):989–93.PubMedCrossRef
25.
Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost. 2010;8(1):54–9.PubMedCrossRef
26.
Tartaglione I, Russo C, Elefante A, Caiazza M, Casale M, Di Concilio R, et al. No evidence of increased cerebrovascular involvement in adult neurologically-asymptomatic β-Thalassaemia. A multicentre multimodal magnetic resonance study. Br J Haematol. 2019;185(4):733–42.PubMedCrossRef
27.
Abdelsamei HA, El-Sherif AM, Ismail AM, Abdel Hakeem GL. The role of the carotid Doppler examination in the evaluation of atherosclerotic changes in β-thalassemia patients. Mediterr J Hematol Infect Dis. 2015;7(1):e2015023.PubMedPubMedCentral
28.
Musallam KM, Beydoun A, Hourani R, Nasreddine W, Raad R, Koussa S, et al. Brain magnetic resonance angiography in splenectomized adults with β-thalassemia intermedia. Eur J Haematol. 2011;87(6):539–46.PubMedCrossRef
29.
Ashjazadeh N, Emami S, Petramfar P, Yaghoubi E, Karimi M. Intracranial blood flow velocity in patients with β-thalassemia intermedia using transcranial Doppler sonography: a case-control study. Anemia. 2012;2012:798296.PubMedCrossRef
30.
• Nassef S, El Shenoufy M, Rawi R, El Demerdash D, Hassan M, Mustafa H, et al. Assessment of atherosclerosis in peripheral and central circulation in adult β thalassemia intermedia patients by color Doppler ultrasound: Egyptian experience. J Vasc Res. 2020;57(4):206–12. In this study the authors found impairment in blood flow and increase in vascular resistance in patients with thalassemia intermedia.
31.
Das S, Dubey S, Acharya M, Chatterjee S, Lahiri D, Das G, et al. Thalassemia and Moyamoya syndrome: unfurling an intriguing association. J Neurol. 2019;266(11):2838–47.PubMedCrossRef
32.
Sébire G, Tabarki B, Saunders DE, Leroy I, Liesner R, Saint-Martin C, et al. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain. 2005;128(Pt 3):477–89.PubMedCrossRef
33.
Ali Taher KM, Cappellini MD. Guidelines for the management of non transfusion dependent thalassaemia (NTDT), vol. 22. 2nd ed. Nicosia (Cyprus): Thalassaemia International Federation; 2017. p. 117.
34.
35.
Akins PT, Glenn S, Nemeth PM, Derdeyn CP. Carotid artery thrombus associated with severe iron-deficiency anemia and thrombocytosis. Stroke. 1996;27(5):1002–5.PubMedCrossRef
36.
Emamikhah M, Yazdi N, Mohebi N, Eslami M, Moghaddasi M. Anemia: an unusual cause of free-floating thrombus of carotid artery. Iran J Neurol. 2019;18(2):87–9.PubMedPubMedCentral
37.
38.
Bibi A, Liyanapthirana C, Khan S. Rare presentation of iron deficiency anaemia with cerebral venous sinus thrombosis in a middle-aged woman. BMJ Case Rep. 2019;12:bcr-2018-225851.PubMedPubMedCentralCrossRef
39.
Bukharovich IF, Wever-Pinzon O, Shah A, Todd G, Chaudhry FA, Sherrid MV. Arterial embolism caused by large mobile aortic thrombus in the absence of atherosclerosis, associated with iron deficiency anemia. Echocardiography. 2012;29(3):369–72.PubMedCrossRef
40.
Gopalratnam K, Woodson KA, Rangunwala J, Sena K, Gupta M. A rare case of stroke secondary to iron deficiency anemia in a young female patient. Case Rep Med. 2017;2017:1684631.PubMedPubMedCentralCrossRef
41.
Maguire JL, deVeber G, Parkin PC. Association between iron-deficiency anemia and stroke in young children. Pediatrics. 2007;120:1053–7.PubMedCrossRef
42.
Leemann B, Boughanem N, Schnider A. L’accident ischémique cérébral, une complication rare de la maladie de Biermer [Ischemic, an uncommon complication of Biermer disease (pernicious anemia)]. Rev Neurol (Paris). 2006;162(10):1007–10.CrossRef
43.
Bougteba A, Basir A, Kissani N. Infarctus cérébral récidivant révélant une maladie de Biermer [Recurrent ischemic stroke revealing Biermer’s disease]. Rev Neurol (Paris). 2009;165(12):1099–102.CrossRef
44.
45.
46.
47.
48.
49.
50.
51.
•• DeBaun MR, Jordan LC, King AA, Schatz J, Vichinsky E, Fox CK, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554–88. https://​doi.​org/​10.​1182/​bloodadvances.​2019001142. Guidelines of the American Society of Hematology regarding management of cerebrovascular disease in patients with sickle cell disease.
52.
53.
54.
55.
56.
57.
Mariani M, Barcellini W, Vercellati C, Marcello AP, Fermo E, Pedotti P, et al. Clinical and hematologic features of 300 patients affected by hereditary spherocytosis grouped according to the type of the membrane protein defect. Haematologica. 2008;93(9):1310–7.PubMedCrossRef
58.
59.
Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet. 2008;372(9647):1411–26.PubMedCrossRef
60.
van Hilten JJ, Haan J, Wintzen AR, van de Nes JC, Heuvelmans JH, Aarts PA, Goslinga H. Cerebral infarction in hereditary spherocytosis. Stroke. 1989;20(12):1755–6.PubMedCrossRef
61.
Ramu CS, Raju GB, Rao KS, Venkateswarlu K. Uncommon neurological manifestations of hemolytic anemia: a report of two cases. Neurol India. 2008;56(2):201–3.PubMedCrossRef
62.
Hayag-Barin JE, Smith RE, Tucker FC Jr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol. 1998;57(1):82–4.PubMedCrossRef
63.
Schilling RF, Gangnon RE, Traver M. Arteriosclerotic events are less frequent in persons with chronic anemia: evidence from families with hereditary spherocytosis. Am J Hematol. 2006;81(5):315–7.PubMedCrossRef
64.
Schilling RF. Spherocytosis, splenectomy, strokes, and heat attacks. Lancet. 1997;350(9092):1677–8.PubMedCrossRef
65.
Schilling RF, Gangnon RE, Traver MI. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost. 2008;6(8):1289–95.PubMedCrossRef
66.
Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ. General haematology task force of the British committee for standards in haematology. Guidelines for the diagnosis and management of hereditary spherocytosis—2011 update. Br J Haematol. 2012;156(1):37–49. PubMedCrossRef
67.
Crary SE, Troendle S, Ahmad N, Buchanan GR. Traditional laboratory measures of cardiovascular risk in hereditary spherocytosis. Pediatr Blood Cancer. 2010;55(4):684–9.PubMedPubMedCentralCrossRef
68.
Gait-Carr E, Connolly DJ, King D. Moyamoya syndrome associated with hereditary spherocytosis: an emerging clinical entity. J Pediatr Hematol Oncol. 2017;39(3):233–4.PubMedCrossRef
69.
70.
71.
72.
73.
Meppiel E, Crassard I, Latour RP, de Guibert S, Terriou L, Chabriat H, Socié G, Bousser MG. Cerebral venous thrombosis in paroxysmal nocturnal hemoglobinuria: a series of 15 cases and review of the literature. Medicine (Baltimore). 2015;94(1):e362.CrossRef
74.
Barcellini W, Scola E, Lanfranconi S, Grottaroli M, Binda F, Fattizzo B, et al. Paroxysmal nocturnal hemoglobinuria (Pnh): brain MRI ischemic lesions in neurologically asymptomatic patients. Sci Rep. 2018;8(1):476.PubMedPubMedCentralCrossRef
75.
Cheng ZJ, Shen YY, Warsame IM, Dai TM, Tu JL. Moyamoya syndrome caused by paroxysmal nocturnal hemoglobinuria. Chin Med J (Engl). 2018;131(23):2874–6.
76.
Ding D, Li K, Li G, Long X. Posterior reversible encephalopathy syndrome following paroxysmal nocturnal hemoglobinuria: a case report and literature review. Int J Clin Exp Med. 2015;8(7):11617–20.PubMedPubMedCentral
77.
Tsai CF, Yip PK, Chen CC, Yeh SJ, Chung ST, Jeng JS. Cerebral infarction in acute anemia. J Neurol. 2010;257:2044–51.
78.
Provenzano R, Fishbane S, Szczech L, Leong R, Saikali KG, Zhong M, et al. Pooled analysis of roxadustat for anemia in patients with kidney failure incident to dialysis. Kidney Int Rep. 2020;6(3):613–23.PubMedPubMedCentralCrossRef
79.
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32.PubMedCrossRef
80.
Eckardt KU, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med. 2021;384(17):1601–12.PubMedCrossRef
81.
Kidney disease: improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012;2:279–335.
82.
Qie S, Jiao N, Duan K, Li J, Liu Y, Liu G. The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review. Int Urol Nephrol. 2021;53(5):985–97.PubMedCrossRef
83.
Ngim CF, Ng CS, Lai NM. Post-transfusion hypertension and seizure in congenital hemolytic anemia: a case report and literature review. J Trop Pediatr. 2014;60(3):253–6.PubMedCrossRef
84.
Inada T, Sadamasa N, Motoie R, Yamana N, Taki W. Cerebral venous thrombosis after red blood cell transfusion for the treatment of iron deficiency anemia. J Stroke Cerebrovasc Dis. 2019;28(11):104338.PubMedCrossRef
85.
Singh K, Gupta R, Kamal H, Silvestri NJ, Wolfe GI. Posterior reversible encephalopathy syndrome secondary to blood transfusion. J Clin Neurosci. 2015;22(3):592–4.PubMedCrossRef
86.
Gaziev J, Marziali S, Paciaroni K, Isgrò A, Di Giuliano F, Rossi G, et al. Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies. Biol Blood Marrow Transplant. 2017;23(9):1531–40.PubMedCrossRef
87.
Barlas RS, Honney K, Loke YK, McCall SJ, Bettencourt-Silva JH, Clark AB, et al. Impact of hemoglobin levels and anemia on mortality in acute stroke: analysis of UK Regional Registry Data, systematic review, and meta-analysis. J Am Heart Assoc. 2016;5(8):e003019.PubMedPubMedCentralCrossRef
88.
Li Z, Zhou T, Li Y, Chen P, Chen L. Anemia increases the mortality risk in patients with stroke: a meta-analysis of cohort studies. Sci Rep. 2016;6:26636.PubMedPubMedCentralCrossRef
89.
Bellwald S, Balasubramaniam R, Nagler M, Burri MS, Fischer SDA, Hakim A, et al. Association of anemia and hemoglobin decrease during acute stroke treatment with infarct growth and clinical outcome. PLoS One. 2018;13(9):e0203535.PubMedPubMedCentralCrossRef
90.
•• Altersberger VL, Kellert L, Al Sultan AS, Martinez-Majander N, Hametner C, Eskandari A, et al. Thrombolysis in Stroke Patients (TRISP) collaborators. Effect of haemoglobin levels on outcome in intravenous thrombolysis-treated stroke patients. Eur Stroke J. 2020;5(2):138–47. This multicenter study reported anemia as an independent predictor of poor outcome and mortality in intravenous thrombolysis-treated stroke patients.
91.
• Akpinar CK, Gurkas E, Aytac E. Moderate to severe anemia is associated with poor functional outcome in acute stroke patients treated with mechanical thrombectomy. Interv Neurol. 2018;7(1–2):12–8. This study demonstrated the association of anemia and poor outcome in stroke patients treated with mechanical thrombectomy.
92.
Chan T, Ganasekaran G. The effect of anemia on the functional outcomes of the stroke patients and the efficiency of their stroke rehabilitation. J Stroke Cerebrovasc Dis. 2015;24(6):1438–42.PubMedCrossRef
93.
Yoshimura Y, Wakabayashi H, Nagano F, Bise T, Shimazu S, Shiraishi A. Low hemoglobin levels are associated with sarcopenia, dysphagia, and adverse rehabilitation outcomes after stroke. J Stroke Cerebrovasc Dis. 2020;29(12):105405.PubMedCrossRef
94.
Yoshimura Y, Wakabayashi H, Shiraishi A, Nagano F, Bise T, Shimazu S. Hemoglobin improvement is positively associated with functional outcomes in stroke patients with anemia. J Stroke Cerebrovasc Dis. 2021;30(1):105453.PubMedCrossRef
95.
•• Zhang S, Pan X, Wei C, Wang L, Cheng Y, Hu Z, et al. Associations of anemia with outcomes in patients with spontaneous intracerebral hemorrhage: a meta-analysis. Front Neurol. 2019;10:406. In this meta-analysis, the authors demonstrated the association between anemia and higher mortality and increased risk of poor outcome in patients with intracranial hemorrhage.
96.
Kuramatsu JB, Gerner ST, Lücking H, Kloska SP, Schellinger PD, Köhrmann M, et al. Anemia is an independent prognostic factor in intracerebral hemorrhage: an observational cohort study. Crit Care. 2013;17(4):R148.PubMedPubMedCentralCrossRef
97.
Kramer AH, Zygun DA, Bleck TP, Dumont AS, Kassell NF, Nathan B. Relationship between hemoglobin concentrations and outcomes across subgroups of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2009;10(2):157–65.PubMedCrossRef
98.
Ayling OGS, Ibrahim GM, Alotaibi NM, Gooderham PA, Macdonald RL. Anemia after aneurysmal subarachnoid hemorrhage is associated with poor outcome and death. Stroke. 2018;49(8):1859–65.PubMedCrossRef
99.
English SW, Fergusson D, Chassé M, Turgeon AF, Lauzier F, Griesdale D, et al. Aneurysmal subarachnoid hemorrhage-red blood cell transfusion and outcome (SAHaRA): a pilot randomised controlled trial protocol. BMJ Open. 2016;6(12):e012623.PubMedPubMedCentralCrossRef
100.
Liu K, Song B, Gao Y, Zhao L, Fang H, Wang Y, et al. Long-term outcomes in patients with anemia and cerebral venous thrombosis. Neurocrit Care. 2018;29(3):463–8.PubMedCrossRef
101.
• Silvis SM, Reinstra E, Hiltunen S, Lindgren E, Heldner MR, Mansour M, et al. Anaemia at admission is associated with poor clinical outcome in cerebral venous thrombosis. Eur J Neurol. 2020;27(4):716–22. In this large and multicenter study, the authors reported the high prevalence of anemia in patients with cerebral venous thrombosis and its association with poor outcome.
Metadaten
Titel
Cerebrovascular Complications of Anemia
verfasst von
Ana Catarina Fonseca
Daniela P. Silva
Joana Infante
José M. Ferro
Publikationsdatum
01.10.2021
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 10/2021
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-021-01141-y

Weitere Artikel der Ausgabe 10/2021

Current Neurology and Neuroscience Reports 10/2021 Zur Ausgabe

Stroke (H. Diener, Section Editor)

Management of Intracerebral Hemorrhage: Update and Future Therapies

Dementia (K.S. Marder, Section Editor)

Molecular Imaging of the Cholinergic System in Alzheimer and Lewy Body Dementias: Expanding Views

Neurology of Systemic Diseases (J.Biller, Section Editor)

Dietary Insights in Neurological Diseases

NEURO-ONCOLOGY (P.Y. WEN, SECTION EDITOR)

Medical and Neurological Management of Brain Tumor Complications

Behavior (H.S. Kirshner, Section Editor)

The Ties that Bind: Agnosia, Neglect and Selective Attention to Visual Scale

Neurology of Systemic Diseases (J. Biller, Section Editor)

Neurological Complications of Pulmonary Embolism: a Literature Review

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise